Diabetic macular oedema treated with intravitreal anti ‐vascular endothelial growth factor – 2–4 years follow‐up of visual acuity and retinal thickness in 566 patients following Danish national guidelines
ConclusionIn a single‐centre clinical setting, 566 patients treated for DME with ranibizumab according to the Danish national guidelines were followed for up to 4 years. Best‐corrected visual acuity (BCVA) outcomes are in the low end of clinical studies, but studied on a wider population and achieved with fewer injections.
Source: Acta Ophthalmologica - Category: Opthalmology Authors: Delila Hodzic ‐Hadzibegovic, Birgit Agnes Sander, Tine Juul Monberg, Michael Larsen, Henrik Lund‐Andersen Tags: Original Article Source Type: research
More News: Databases & Libraries | Denmark Health | Diabetes | Endocrinology | Eyes | Lucentis | Opthalmology | Ranibizumab Injection | Statistics | Study | Vitamin A